Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

80 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
GL
Xilio Therapeutics : Corporate Update Call
PU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
BU
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
AQ
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
GL
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
AQ
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
GL
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
AQ
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
GL
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
AQ
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
AQ
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
GL
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
AQ
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
GL
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
GL
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
GL
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
AQ
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
GL
ReFrame and IMDbPro Announce 2022 ReFrame Stamp Film Recipients
BU
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
GL
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
GL
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
AQ
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
AQ
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
GL
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
GL
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
GL
XILIO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
GL
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
GL
Xilio Therapeutics : Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
GL
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
AQ
Adagio Therapeutics : Announces David Hering Appointed Interim Chief Executive Officer - Form 8-K
PU
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
AQ
Xilio Therapeutics : Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results - Form 8-K
PU
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
AQ
X4 PHARMACEUTICALS, INC : Change in Directors or Principal Officers (form 8-K)
AQ
X4 Pharmaceuticals, Inc. Approves Resignation of Ren? Russo as Director
CI
Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer
BU
Climate change and monetary policy in the euro area
PU
Transcript : Portland General Electric Company, Q1 2021 Earnings Call, Apr 30, 2021
The Latin Recording Academy :® Announces 21st Annual Latin GRAMMY Awards® Nominees
BU
Celsius Therapeutics : Announces Key Leadership Appointments
BU
Akrevia Therapeutics : Appoints René Russo, PharmD, as Chief Executive Officer
PR
No results for this search
  1. Stock Market
  2. Advanced search
  3. Ren� Russo
  4. News